• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

Trader Who Called Shiba Inu's Surge Predicts 24,050% Growth for Rexas Finance

user avatar

by Giorgi Kostiuk

a year ago


The trader known for accurately predicting the rise of Shiba Inu has now shared his forecast for the Rexas Finance (RXS) token. According to him, RXS could increase by 24,050% following Donald Trump's inauguration as President of the USA.

Rexas Finance Presale Success

Launched in September 2024, Rexas Finance has quickly become popular for its innovative real-world asset tokenization model. The company offers investors the opportunity to buy shares in assets like real estate and art, thus lowering the entry barrier for investments and increasing market transparency. The RXS presale is a major success: in the tenth stage, one token is priced at $0.150, with the next stage set at $0.175. Over $31 million of the targeted $33 million has already been raised, reflecting strong investor interest.

Forecasts and Expectations

The trader's predictions, who previously forecasted Shiba Inu's fate, are indeed surprising again. He believes that the RXS token could rise by 24,050% within weeks. Such a forecast is supported by the fact that many investors are looking for opportunities beyond Bitcoin and Ethereum, showing interest in real assets and their integration into blockchain technology.

Conclusion: Potential and Prospects

Rexas Finance offers a fresh perspective on investments by linking them to real assets through blockchain technology. The presale's success and ambitious predictions make the project appealing to both seasoned and new investors. Despite incredible forecasts, the potential of RXS remains widely discussed.

Rexas Finance presents a unique approach to investing in real-world assets, attracting attention from both seasoned and new investors. Given the successful presale and ambitious forecasts, the project remains a topic of discussion.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

BioAge Labs Focuses on Metabolic Aging with AI

chest

BioAge Labs is utilizing machine learning to explore metabolic aging and develop treatments for metabolic disorders.

user avatarAyman Ben Youssef

Neumora Therapeutics Targets Brain Diseases with AI

chest

Neumora Therapeutics is developing AI-driven solutions for treating brain diseases, including schizophrenia and Alzheimer's.

user avatarSon Min-ho

Relay Therapeutics Innovates Drug Discovery with AI

chest

Relay Therapeutics is using its AI-powered platform to enhance drug discovery processes in oncology.

user avatarJacob Williams

AI Advances in Biotech: Nobel Prize Winners and Promising Companies

chest

In 2024, the Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John Jumper for their groundbreaking work in using machine learning to design entirely new proteins, highlighting the growing role of AI in biotech.

user avatarTando Nkube

OBBBA Law Restores R&D Deductions for Biotech Companies

chest

The One Big Beautiful Bill Act restores 100% deduction of R&D expenses for biotech companies, aimed at revitalizing domestic industries and reducing financial pressure.

user avatarZainab Kamara

Launch of OTCfi Token on Olympus Chain

chest

Launch of OTCfi Token on Olympus Chain as part of the partnership between Metavesco and BLAQclouds, aimed at expanding utility in crypto and OTC markets.

user avatarAisha Farooq

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.